Coffee Increases Physical and Cognitive Performance Both in Men and Women

NCT07474753 | Completed

• 1 other identifier: İ3-149-20
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

The impact of caffeine habituation on acute responses to different doses of caffeinated coffee has received minimal attention. This study aimed to investigate the effects of different doses of coffee on physical and cognitive performance in men and women with different levels of daily caffeine consumption. Sixty-nine (35 women) athletes participated in this study, attending 4 experimental visits in a double-blind, randomized, crossover fashion: decaffeinated coffee (PLA), 1.5 mg·kg-1 (LCOF), 3 mg·kg-1 (MCOF) and 6 mg·kg-1 of caffeine (HCOF) from coffee ingestion. Sixty min after coffee consumption, participants performed squat and bench press exercises (1 repetition maximum, 1RM), 60% of 1RM muscular endurance (ME), maximal sprinting, and cognitive performance (CP) was assessed. Participants were allocated into low (LGROUP), moderate (MGROUP), and high (HGROUP) caffeine consumption groups.

Conditions

Dietary Supplement; Exercise

Outcome Measures

Primary Outcomes (2)

• Upper- and Lower-boy muscular endurance

  Muscular endurance assessed during bench press and squat exercises using 60% of one-repetition maximum (1RM). Performance expressed as total weight lifted (kg).

  60 minutes after caffeine or placebo ingestion (during each experimental trial)

• Upper- and lower-body strenght

  Maximal dynamic strength assessed using one-repetition maximum (1RM) tests in the squat and bench press exercises (kg).

  60 minutes after caffeine or placebo ingestion (during each experimental trial)

Secondary Outcomes (2)

• Sprint Performance

  60 minutes after caffeine or placebo ingestion (during each experimental trial)

• Cognitive performance

  Baseline (before caffeine ingestion) and 60 minutes after caffeine or placebo ingestion.

Study Arms (4)

Low dose caffeine supplementation

EXPERIMENTAL

consuming 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake 60-min before the experimental trial.

Dietary Supplement: Low Dose Caffeine (LCOF)

Moderate dose caffeine supplementation

EXPERIMENTAL

Consuming 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake 60-min before the experimental trial.

Dietary Supplement: Moderate Dose Caffeine (MCOF)

High dose caffeine supplementation

EXPERIMENTAL

Consuming 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake 60-min before the experimental trial.

Dietary Supplement: High Dose Caffeine (HCOF)

Placebo

EXPERIMENTAL

Consuming 0.16 g·kg-1 of decaffeinated coffee 60-min before the experimental trial.

Dietary Supplement: Placebo (PLA)

Interventions

Low Dose Caffeine (LCOF) DIETARY_SUPPLEMENT

Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.12 g·kg-1 of decaffeinated coffee + 0.04 g·kg-1 of caffeinated coffee to achieve 1.5 mg·kg-1 of caffeine intake in LCOF 60-min before the experimental trial.

Low dose caffeine supplementation

Moderate Dose Caffeine (MCOF) DIETARY_SUPPLEMENT

Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.08 g·kg-1 of decaffeinated coffee + 0.08 g·kg-1 of caffeinated coffee to achieve 3 mg·kg-1 of caffeine intake in MCOF 60-min before the experimental trial.

Moderate dose caffeine supplementation

High Dose Caffeine (HCOF) DIETARY_SUPPLEMENT

Caffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of caffeinated coffee to achieve 6 mg·kg-1 of caffeine intake in HCOF 60-min before the experimental trial.

High dose caffeine supplementation

Placebo (PLA) DIETARY_SUPPLEMENT

Decaffeinated versions of instant coffee were prepared in 600 ml hot water (approximately 65°C) and served in a mug. Participants ingested 0.16 g·kg-1 of decaffeinated coffee in PLA 60-min before the experimental trial.

Placebo

Eligibility Criteria

• Age: 18 Years - 30 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy individuals
• Physically active individuals
• Non-smokers
• Age between 18 and 30 years
• Free from respiratory insufficiency
• Free from cardiovascular disease
• Free from neuromuscular disorders
• Free from musculoskeletal injury within the previous 6 months

You may not qualify if:

• Diagnosed cardiovascular disease
• Neuromuscular disease
• Current limb injury
• History of limb injury requiring treatment within the previous 6 months
• Chronic respiratory disease or treatment for chronic respiratory conditions

Sponsors & Collaborators

• Northumbria University: lead

Study Sites (1)

Ankara University's Department of Sports Science

Ankara, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Motor Activity

Interventions

Caffeine

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Supplements were allocated in a randomised order and double-blinding design was implemented by an independent technician who did not take part in the study. The randomisation and blinding were held until the end of the study.
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: February 6, 2026
• First Posted: March 16, 2026
• Study Start: December 4, 2020
• Primary Completion: March 20, 2021
• Study Completion: March 20, 2021
• Last Updated: March 16, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)